The microbiome mediates its effect via release of metabolites and we feel that metabolites can also be used therapeutically if we know which ones are triggering which function and this is clearly context-dependent. So what we find is that bacterial metabolites in allo-HCT can be protective under certain conditions if applied in preclinical model systems to prevent GVHD...
The microbiome mediates its effect via release of metabolites and we feel that metabolites can also be used therapeutically if we know which ones are triggering which function and this is clearly context-dependent. So what we find is that bacterial metabolites in allo-HCT can be protective under certain conditions if applied in preclinical model systems to prevent GVHD. But at the same time, if you use some metabolites at higher doses, they can also prime graft-versus leukemia responses. Currently, this is of course a danger because we know that there needs to be a tight balance between preventing GVHD, treating it and also inducing Graft-Versus-Leukemia (GVL) because that poses the risk of inducing severe GVHD. So I think we still need to find the perfect balance in which metabolites to use. But I think encapsulating metabolites, utilizing metabolic cocktails for future clinical trials is one way to go to improve outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
